The high frequency of anti-PF4/heparin antibodies in patients with COVID-19 is neither related to heparin treatment or to an increased incidence of thrombosis

Clin Chem Lab Med. 2021 Jun 30;59(11):e405-e408. doi: 10.1515/cclm-2021-0623. Print 2021 Oct 26.
No abstract available

Keywords: COVID-19; anti-PF4/heparin antibodies; heparin induced thrombocytopenia.

MeSH terms

  • Aged
  • Antibodies / metabolism*
  • Blood Platelets / metabolism
  • COVID-19 Drug Treatment*
  • Female
  • Heparin / metabolism*
  • Humans
  • Immunoglobulin A / metabolism
  • Immunoglobulin G / metabolism
  • Immunoglobulin M / metabolism
  • Incidence
  • Male
  • Middle Aged
  • Platelet Factor 4 / metabolism*
  • SARS-CoV-2 / drug effects*
  • Thrombosis / chemically induced*
  • Thrombosis / metabolism

Substances

  • Antibodies
  • Immunoglobulin A
  • Immunoglobulin G
  • Immunoglobulin M
  • PF4 protein, human
  • Platelet Factor 4
  • Heparin